An index for assessing blindness in a multi-centre clinical trial: Disulfiram for alcohol cessation - A VA cooperative study

Statistics in Medicine

Volumn 15, Issue 13, 1996, Pages 1421-1434

  James, Kenneth E ^a   Block, Daniel A ^b   Lee, Kelvin K ^c   Kraemer, Helena C ^b   Fuller, Richard K ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIRAM;

ALCOHOL ABSTINENCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MULTICENTER STUDY; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOLISM; BIAS (EPIDEMIOLOGY); DISULFIRAM; DOUBLE-BLIND METHOD; HOSPITALS, VETERANS; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 0030013129     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19960715)15:13<1421::AID-SIM266>3.0.CO;2-H     Document Type: Article

References (16)

1. Byington, R. P., Curb, J. D., Mattson, M. E., for the Beta-Blocker heart Attack Trial Research Group. 'Assessments of double-blindness at the conclusion of the Beta-Blocker Heart Attack Trial', Journal of the American Medical Association, 253, 1733-1736 (1985).
2. Moscucci, M., Byrne, L., Weintraub, M. and Cox, C. 'Blinding, unblinding, and the placebo effect: An analysis of patients' guesses of treatment assignment in a double-blind clinical trial', Clinical Pharmacology and Therapeutics, 41, 259-265 (1987).
3. Howard, J., Whittemore, A. S., Hoover, J. J., Panos, M. and the Aspirin Myocardial Infarction Study Research Group. 'Commentary: How blind was the patient blind in AMIS?', Clinical Pharmacology and Therapeutics, 32, 543-553 (1982).
4. Hughes, J. R. and Krahn, D. 'Blindness and variability of the double-blind procedure', Journal of Clinical Psychopharmacology, 5, 138-142 (1985).
5. Bownell, K. D. and Stunkard, A. J. The double-blind in danger: Untoward consequences of informed consent', American Journal of Psychiatry, 139, 1487-1489 (1982).
6. Deyo, R. A., Walsh, N. E., Schoenfield, L. S. and Ramamurthy, S. 'Can trials of physical treatment be blinded', American Journal of Physical Medicine and Rehabilitation, 69, 6-10 (1990).
7. Jesperson, C. M. and the Danish Study Group on Verapamil in Myocardial Infarction. 'Assessment of blindness in the Danish Verapamil Infraction Trial II (DAVIT II)', European Journal of Clinical Pharmacology, 39, 75-76 (1990).
8. Marini, J. L., Sheard, M. H., Bridges, C. I. and Wagner, E. 'An evaluation of the double-blind design in a study comparing lithium carbonate with placebo', Acta Psychiat. Scand., 53, 343-354 (1976).
9. Fuller, R. K., Branchy L., Brightwell, D., Derman, R. M., Emrick, C. D. et al. 'Disulfiram treatment of alcoholism: A Veterans Administration cooperative study', Journal of the American Medical Association, 256, 1449-1455 (1986).
10. Fuller, R. K., Williford, W. O., William, O., Lee, K. K. and Derman, R. 'Veterans Administration cooperative study of disulfiram for the treatment of alcoholism: Study design and methodological considerations', Controlled Clinical Trials, 5, 263-273 (1984).
11. Fleiss, J. L. Statistical Methods for Rates and Proportions, 2nd edn, Wiley, New York, 1977, p. 219.
12. Efron, B. The Jackknife, Bootstrap, and Other Resampling Plans, Society for Industrial and Applied Mathematics, Philadelphia, 1982.
13. Moses, L. E. Think and Explain with Statistics, Addison-Wesley, Menlo Park, 1986, p. 433.
14. Oxtoby, A., Jones, A. and Robinson, M. 'Is your double-blind design truly double-blind?', British Journal of Psychiatry, 155, 700-701 (1989).
15. Newcombe, R. G., 'Letter to the editor', British Journal of Psychiatry, 156, 282 (1990).
16. Fisher, R. A. Statistical Methods for Research Workers, 13th edn, Hafner, New York, 1958, p. 309.